Clinical Trial

Guselkumab for Overlap Inflammatory Bowel Disease and Spondyloarthritis

Study acronym: GLOBE-SpA
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This is an observational study of a prospective cohort of guselkumab-initiating Crohn's Disease (CD) and Ulcerative Colitis (UC) patients to identify new or incident spondyloarthritis. This study will include adult patients aged 18-75 with IBD who are undergoing guselkumab intravenous or subcutaneous induction over a 1-year timeframe.
Trial Details
NCT Number NCT07602517
Lead Sponsor NYU Langone Health
Collaborators: Janssen Scientific Affairs, LLC
Conditions Spondyloarthritis, Inflammatory Bowel Diseases
Enrollment 75 participants
Start Date 2026-05-20
Primary Completion 2028-05-20 (estimated)
Study Completion 2029-05-20 (estimated)
Updated on ClinicalTrials.gov 2026-05-22